Targeting HSP90 for cancer therapy by Mahalingam, D et al.
Minireview
Targeting HSP90 for cancer therapy
D Mahalingam
1, R Swords
1, JS Carew
1, ST Nawrocki
1, K Bhalla
2 and FJ Giles*,1
1Institute for Drug Development, Cancer Research and Therapy Centre at the University of Texas Health Science Centre, San Antonio, TX, USA;
2MGC Cancer Centre, Medical College of Georgia, Augusta, GA, USA
Heat-shock proteins (HSPs) are molecular chaperones that regulate protein folding to ensure correct conformation and translocation
and to avoid protein aggregation. Heat-shock proteins are increased in many solid tumours and haematological malignancies. Many
oncogenic proteins responsible for the transformation of cells to cancerous forms are client proteins of HSP90. Targeting HSP90 with
chemical inhibitors would degrade these oncogenic proteins, and thus serve as useful anticancer agents. This review provides an
overview of the HSP chaperone machinery and the structure and function of HSP90. We also highlight the key oncogenic proteins
that are regulated by HSP90 and describe how inhibition of HSP90 could alter the activity of multiple signalling proteins, receptors
and transcriptional factors implicated in carcinogenesis.
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Heat-shock proteins (HSPs) are a highly conserved family of
molecular chaperones, some of which are induced by sublethal
cellular stresses, including temperature elevation, hypoxia and
oxidative damage (Young et al, 2004). The transcription of
inducible HSPs is regulated by heat-shock factors (HSFs) in
particular HSF1 (Xiao et al, 1999). Once present in the cell,
induced HSPs provide a transient protection from subsequent,
potentially lethal stress. Heat-shock proteins regulate protein
folding to ensure correct conformation and translocation and to
avoid aggregate formation (Young et al, 2004).
Heat-shock proteins are found at increased levels in many solid
tumours and haematological malignancies. Their expression may
in part account for the ability of malignant cells to maintain
protein homoeostasis even in the hostile hypoxic and acidotic
microenvironment of the tumour. Likewise, HSPs allow tumour
cells to tolerate genetic alterations that would otherwise be fatal
(Bagatell, 2004). Therefore, targeting of HSPs with chemical
inhibitors may disrupt multiple oncogenic processes. There has
thus been increased interest in the development of small molecule
inhibitors that target individual HSPs to alter their function and
cause the proteasomal degradation of their oncogenic ‘client’
proteins (Solit and Chiosis, 2008).
THE HEAT-SHOCK RESPONSE (HSR)
Chaperone proteins ensure protein homoeostasis in the presence
and absence of cellular stress. In the event of protein damage,
molecular chaperones facilitate protein refolding or, if the damage
is irreversible, target the protein for degradation. Chaperones also
participate in the post-translational modification of signalling mole-
cules, the assembly and disassembly of transcriptional complexes
and the modulation of immunogenic proteins (Bagatell, 2004).
Molecular chaperones belong to a group of highly conserved
proteins called HSPs, which are classified into families according
to molecular size including, HSP100, HSP90, HSP70, HSP60 and
small HSP (15–30kDa) (Young et al, 2004; Powers and Workman,
2007). Although the high molecular weight HSPs are adenosine
triphosphate (ATP)-dependent, the small HSPs act in an ATP-
independent manner (Jakob et al, 1993). Heat-shock proteins act
in concert with co-chaperones and adaptor molecules to form large
multiprotein complexes (Young et al, 2004; Wandinger et al, 2008).
The rapid induction of HSPs in response to stress is a result of a
coordinated series of genetic and biochemical events referred to as
the HSR. The HSR is mediated by HSFs. Of the three human HSFs,
HSF1, 2 and 4, HSF1 is most crucial to the HSR (Xiao et al, 1999;
Powers and Workman, 2007). In response to stress, HSF1 is
activated by dissociation from its complex with HSP90 and HSP70.
Heat-shock factor 1 binding to the heat-shock element drives the
expression of responsive genes. The HSP mRNA lack introns and
so are efficiently transcribed in the stressed environment without a
requirement for ATP-dependent post-translational modification.
Many tumours show increased levels of HSPs (Bagatell, 2004;
Whitesell and Lindquist, 2005). Heat-shock proteins promote
tumour cell survival, growth and metastasis, even in growth factor-
deprived conditions, by allowing continued protein translation and
cellular proliferation (Whitesell and Lindquist, 2005). Heat-shock
factor 1 knockout mice show reduced development of tumours,
and HSF1 deficiency rendered cultured cells highly refractory to
transformation initiated by mutated RAS or by platelet-derived
growth factor-B (PDGF-B) overexpression (Dai et al, 2007; Min
et al, 2007). Similarly, HSF1 depletion decreased viability of
multiple human cancer cell lines, but had no effect on normal cells,
suggesting that HSF1 provides critical relief to the cellular stresses
experienced by cancer cells (Dai et al, 2007). Evidence also suggest
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induction of HSPs, such as HSP90, but also by orchestrating a
broad network of core cellular functions that include proliferation,
survival, protein synthesis and energy metabolism (Birch-Machin
et al, 2005; Dai et al, 2007). Therefore, non-oncogenes like HSF1,
whose functions are critical to cancer cells but dispensable to
normal cells, can particularly be attractive as cancer drug targets
(Solimini et al, 2007).
Although inhibitors of HSP90 and the proteasome disrupt
chaperone machinery, they can also activate the HSR (Powers and
Workman, 2007). This inadvertent induction of HSPs may
attenuate the beneficial effects of HSP90 inhibitors (Banerji et al,
2005). Studies have found that the expression of both the major
constitutive heat-shock cognate 70 (HSC70) and inducible isoform
(HSP72) are increased following HSP90 inhibition with depletion
of both these isoforms using short interfering RNA (siRNA) before
HSP90 inhibition enhances HSP90 inhibitor cytotoxicity (Gabai
et al, 2005; Powers et al, 2008). Translating these preclinical studies
into early clinical trials, investigators have used the induction of
HSP70 as a pharmacodynamic marker of HSP90 inhibition in both
tumour tissue and peripheral blood lymphocytes (PBLs; Modi
et al, 2007b). Whether induction of HSP70 following HSP90
inhibition attenuates the cytotoxic effects of HSP90 inhibitors
remains to be determined as clinical trials mature.
As expected, studies combining inhibitors of both HSP90 and
the proteasome result in the accumulation of ubiquitinated
misfolded oncogenic proteins and a synergistic cytotoxicty
(Mimnaugh et al, 2004). These findings have driven the design
and implementation of clinical trials in multiple myeloma, where
the proteasome inhibitor bortezomib has already been approved
for therapeutic use.
Heat-shock protein 90 STRUCTURE AND FUNCTION
The HSP90 is a constitutively expressed cellular protein that
compromises 1–2% of the total protein load. It is a flexible
homodimer whose monomers consist of three domains, an
N-terminal, ATP-binding domain, a middle (M), ATP-hydrolysis-
regulating domain and a C-terminal or dimerisation domain
(Wandinger et al, 2008). The C-terminus also regulates ATPase
activity and recruits co-chaperones through a conserved EEVD
motif (Wandinger et al, 2008). Co-chaperones, containing tetra-
tricopeptide repeat (TPR) domains, such as HOP and PPIase, and
the non-TPR co-chaperones, CDC37, p23 and Aha1, play an
important role in client protein maturation and modulation of
ATPase activity (Pratt and Toft, 2003; Young et al, 2004;
Wandinger et al, 2008). Co-chaperones also recruit specific client
proteins to HSP90 and/or stabilise HSP90 in an ATP-bound state
to prolong the half-life of the mature multichaperone complex
(Whitesell and Lindquist, 2005). Adenosine triphosphate hydro-
lysis alters HSP90 structure and promotes its chaperone function
(Whitesell and Lindquist, 2005).
Five HSP90 isoforms have been identified to date, including
cytoplasmic HSP90a- and b-isoforms, endoplasmic reticulum
localised glucose regulated protein 94 (GRP94), mitochondrial
tumour necrosis factor receptor-associated protein 1 (TRAP1) and
membrane-associated HSP90N (Powers and Workman, 2007). All
isoforms have a similar structure, except for HSP90N, which
possesses a blunt N-terminus lacking an ATP-binding region
(Powers and Workman, 2007). Figure 1 illustrates how HSPs
regulate protein stability and maturation by formation of large
multiprotein chaperone complexes.
Heat-shock protein 90 function can be further regulated by post-
translational modifications, phosphorylation, nitrosylation and
acetylation (Wandinger et al, 2008). Hyperacetylation of HSP90
occurs following histone deacetylase 6 (HDAC6) inhibition and is
observed in HDAC6-deficient mouse embryonic fibroblasts and
correlates with impaired HSP90 function (Zhang et al, 2008).
Hyperacetylation attenuates HSP90 chaperoning of client proteins
BCR-ABL, AKT, RAF1 and hormone receptors, such as the
glucocorticoid receptor results in cellular cytotoxicity (Kovacs
et al, 2005; Fiskus et al, 2007; Wandinger et al, 2008). These
findings may explain the synergy observed between HDAC
inhibitors and oncoprotein kinase inhibitors used against specific
HSP90 client proteins (Fiskus et al, 2006).
HSP90 AND THE DEVELOPMENT OF CANCER
Many oncogenic proteins are HSP90 client proteins. Table 1
depicts the list of client proteins discussed below, mechanism of
actions of these proteins and potential tumours that HSP90
inhibitors could be applied to.
Prosurvival signalling molecules
Growth factors drive tumour cell proliferation through transmem-
brane-bound receptor tyrosine kinases (RTKs), which are fre-
quently overexpressed and/or mutated in cancer cells (Scaltriti
and Baselga, 2006). The epidermal growth factor receptor (EGFR)
is an RTK, which can be activated in a ligand-dependent and
-independent manner or when overexpressed (Scaltriti and
Baselga, 2006). Recently, several somatic mutations in the EGFR
gene have been linked with favourable response to treatment
with anti-EGFR tyrosine kinase inhibitors (TKIs), gefitinib and
erlotinib, in non-small cell lung cancer (NSCLC) patients (Scaltriti
and Baselga, 2006). Tumours with these mutations are also
sensitive to HSP90 inhibitors despite developing resistance to
TKIs. Tumour cells without EGFR mutations are equally resis-
tance to both TKIs and HSP90 inhibitors (Shimamura et al, 2008)
emphasising the importance of patient selection when designing
clinical trials. Once active, EGFR is phosphorylated to initiate a
series of biochemical signalling events, which diverge to activate
the phosphatidylinositol 3-kinase AKT (PI3K-AKT) pathway,
the Ras-Raf-extracellular signal-regulated kinase (Ras-Raf-ERK)
pathway and the stress-activated protein kinase pathway. These
prosurvival pathways culminate in DNA synthesis, cell division
and tumour cell proliferation (Scaltriti and Baselga, 2006).
The active PI3K-AKT pathway activates prosurvival transcrip-
tion factors, such as nuclear factor-kB (NF-kB). AKT suppress
proapoptotic proteins, for example, the Forkhead transcription
factor family and Bad (Jiang and Liu, 2008). Mutations in the AKT
pathway, its constitutive activation or the loss of the tumour
suppressor PTEN, will fuel tumour cell proliferation and prevent
apoptosis (Jiang and Liu, 2008). As a HSP90 client protein, AKT
degradation following HSP90 inhibition would result in attenua-
tion of its prosurvival effects (Sato et al, 2000).
The Ras-Raf-ERK pathway is similarly important in cell
proliferation and survival. Mutations in N-Ras and/or B-Raf
constitutively activate signalling (Grbovic et al, 2006). Mutated
B-Raf is a known HSP90 client protein. Therefore, HSP90
inhibition disrupts the mutant B-Raf and reduces ERK signalling
(Grbovic et al, 2006). Clinical responses have been observed in
patients with metastatic malignant melanoma treated with the
HSP90 inhibitor 17-AAG (Banerji et al, 2008) and were associated
with B-Raf and N-Ras mutations, leading to a phase II trial of the
HSP90 inhibitor tanespimycin in patients with malignant melano-
ma, on which clinical activity has also been observed.
ErbB2/HER-2 is another tyrosine kinase overexpressed in
approximately 20–30% of breast and prostate cancers. The HER-
2 protein stability is inherently dependent on HSP90. Heat-shock
protein 90 inhibition decreased ErbB2 protein, phosphorylated
HER-2 and downstream prosurvival signalling (Solit et al, 2002).
Early clinical trials with tanespimycin in combination with the
monoclonal HER-2 antibody, traztuzumab, showed modest clinical
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Figure 1 The binding of a client protein to HSP90 requires the co-operation of HSP90 with another chaperone, HSP70 and its co-factor HSP40. Both
HSP90 and HSP70 chaperones are further linked by an adapter protein called HOP, which binds to both HSP90 and HSP70 through the small helical TPR
domains to the C-terminal ends of HSP90 and HSP70. Aha1 is a co-factor that can bind and stimulate activity of HSP90 ATPase. When HSP90 exchanges ADP
for ATP, it undergoes conformational change, which dissociates from the HSP70/HSP40/HOP complex, allowing ATP-dependent interaction with other co-
chaperones, such as CDC37 and p23, to form a mature complex. It is in this mature state that HSP90 that allows client protein activation following cellular
stresses, including phosphorylation of AKT, binding of EGFR to its ligands and ensuring transcription factors, such as HIF-1a and p53, to express genes. Inhibition
of ATP-binding through HSP inhibitors prevents client protein maturation and result in degradation of these oncogenic proteins by the proteasome.
Table 1 A selected list of HSP90 client proteins, mechanism of actions of these proteins and potential target tumours that HSP90 inhibitors could be
applied to
Class of protein
Client protein or interacting
protein of HSP90 Mechanism of action Potential target cancer
Receptor tyrosine kinase EGFR mutant Activation of downstream prosurvival pathways, such as
PI3K-AKT and MAPK.
NSCLC and glioblastoma
ErbB2/HER-2 Breast cancer
KIT GIST
Signalling molecules or kinases AKT Activation of prosurvival proteins and suppression of
proapoptotic proteins
Various cancers
B-Raf mutant Constitutively activates ERK signalling Melanoma
MET Involved in cellular proliferation, migration, invasion and
morphogenesis
Gastric, lung
CDK4 Phosphorylates and inactivates Rb, allowing cell cycle to
proceed
Tumours with CDK4
overexpression
Death domain kinase RIP Allows activation of NF-kB and its antiapoptotic signals
Transcriptional factors HIF-1a Promoting angiogenesis Renal cancer
ERa-receptors Regulating genes involved in cellular proliferation Breast cancer
P53 mutant Transcription of genes involved in cell cycle arrest or
apoptosis
Mutated in B50% of
cancer
Chimeric fusion-proteins BCR-ABL Activates numerous signal transduction pathways in
leukaemogenesis
CML
NPM-ALK Induces cell transformation and proliferation Anaplastic lymphoma
Others Telomerase Prevents telomere shortening Various cancers
Apaf-1 Crucial for apoptosome formation
Bcl-2 Regulates mitochondrial apoptotic pathway Follicular lymphoma/small
cell lung cancer
MMP2 Facilitates invasion through cell adhesion, matrix digestion
and cell migration
Overexpressed in various
cancers
CDK4= cyclin dependent kinase 4; CML¼chronic myeloid leukaemia; EGFR¼epidermal growth factor receptor; ER¼oestrogen receptor; GIST¼gastrointestinal stromal
tumours; HIF¼hypoxia-inducible factor; HSP¼heat-shock protein; MAPK= mitogen activated protein kinase; NSCLC= non-small cell lung cancer; Rb¼retinoblastoma;
RIP¼receptor-interactingprotein.
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overexpressing tumours (Modi et al, 2007b). The maximum
tolerated dose was not achieved and dose escalation was
terminated at 450mgm
 2. Following from this, the phase II trial
has reported encouraging response rates in patients with HER-2-
positive breast cancer, who progressed within 3 months of
adjuvant traztuzumab therapy (Modi et al, 2007a). Interestingly,
HSP70 induction, used as a pharmacodynamic marker of HSP90
inhibition, was observed in PBLs within 24h of drug administra-
tion in the phase I trial (Modi et al, 2007b). This again raises the
question as to whether the induction of HSP70 limits the clinical
benefits of HSP90 inhibition.
KIT, another RTK, undergoes gain-of-function mutation in
490% of gastrointestinal stromal tumours (GISTs) leading to the
activation of PI3K-AKT, mitogen-activated protein kinase
(MAPK), STAT-1 and STAT-3 prosurvival pathways (Duensing
et al, 2004). Inhibition of KIT oncoprotein by imatinib mesylate
(Gleevec, Novartis, Basel, Switzerland) induces a clinical response
in most GIST patients. However, many patients eventually develop
resistance because of further KIT mutations. Salvage treatment
with TKIs led to a median survival of only 15 months (Bauer et al,
2006). It was subsequently shown that KIT activation depended on
protein stabilisation by HSP90. Heat-shock protein 90 inhibition
caused degradation of both wild-type and imatinib-resistant KIT
mutants (Fumo et al, 2004). Similarly, HSP90 inhibitors substan-
tially reduced phosphorylated-KIT and total KIT expression with
decreased cell survival observed in KIT-positive GIST (Bauer et al,
2006). This led to a phase I trial of the HSP90 inhibitor
IPI-504 in patients with refractory metastatic GIST who had
progressed on TKI therapy. Although no response was seen based
on RECIST criteria, FDG–PET responses based on the EORTC
criteria were observed in 15 of the 18 patients (Demetri et al, 2006).
This raises the question of what parameters of clinical response
should clinical investigators look for when designing clinical trials
with HSP90 inhibitors.
Steroid hormone receptors
The oestrogen receptor-a (ERa) is an intracellular transcription
factor that transduces a signal following binding of its ligand,
oestradiol. Growing evidence suggests that ERa may be activated
independent of oestradiol through the downstream signalling
pathways of other activated growth factor receptors (Martin et al,
2000). Activated ERa plays a role in breast cancer by regulating
genes involved in cellular proliferation (Sommer and Fuqua, 2001).
In the absence of oestradiol, ERa is found in the nucleus as part of
a multiprotein complex containing HSP90 and other chaperones
(Fliss et al, 2000). Upon ligation, ERa dissociates from the complex
and binds oestrogen response elements in the promoters of
oestradiol-responsive genes; progesterone receptor, cathepsin D
and HDAC6 (Fliss et al, 2000). Oestrogen receptor-a may also
localise at the plasma membrane to activate EGFR and insulin-like
growth factor receptor and signal downstream events (Levin,
2003).
Heat-shock protein 90 inhibitors target ERa for proteasomal
degradation (Whitesell and Lindquist, 2005), and as such may be
useful in the treatment of ER-positive breast cancers. In addition,
HSP90 inhibitors may be beneficial in patients who develop
resistance to hormone therapies, tamoxifen or aromatase inhibi-
tors (Beliakoff et al, 2003). These inhibitors prevent ligand-
independent activation of ERa by preventing ERa phosphorylation
and degrading AKT (Sato et al, 2000; Beliakoff et al, 2003).
Chimeric fusion proteins
Chronic myeloid leukaemia (CML) is characterised by the
BCR-ABL fusion gene, which is a constitutively active cytoplasmic
tyrosine kinase that activates numerous signal transduction
pathways and contributes to leukaemogenesis (Druker et al,
2001). Imatinib mesylate targets the ATP-binding site of the kinase
domain of ABL and prolongs survival in all phases of CML
(Druker et al, 2001). However, patients can develop imatinib
resistance associated with BCR-ABL gene amplification and/or
kinase domain mutations, which abrogate imatinib-binding or
function (Gorre et al, 2001). Heat-shock protein 90 maintains
BCR-ABL stability and function (Nimmanapalli et al, 2001).
Therefore, HSP90 inhibitors targets BCR-ABL for degradation
and suppresses cell proliferation (Nimmanapalli et al, 2001).
Furthermore, HDAC inhibitors shown to effectively induce
apoptosis in both imatinib-sensitive and -resistant BCR-ABL
myeloid leukaemia cells can be used in combination with HSP90
inhibitors to synergistically induce apoptosis and inhibit cell
growth (Rahmani et al, 2005).
Anaplastic large cell lymphomas are a subgroup of non-
Hodgkins lymphoma, which are characterised by the expression
of the chimeric protein, NPM-ALK. NPM-ALK originates from the
fusion of nucleophosmin (NPM) and the membrane receptor,
anaplastic lymphoma kinase (ALK; Hubinger et al, 1999). Similar
to RTK, dimerisation is required for NPM-ALK activation,
although, however, unlike RTKs, NPM-ALK dimers are constitu-
tively active and do not require plasma membrane localisation
(Fujimoto et al, 1996). Active NPM-ALK possesses phospho-
transferase activity and interacts with various ALK-adapter
proteins to induce cell transformation and proliferation (Hubinger
et al, 1999). Both HSP90 and HSP70 bind NPM-ALK. Heat-shock
protein 90 inhibition causes NPM-ALK destabilisation and
degradation and reduces ALK-adapter protein phosphorylation.
Although HSP90 inhibition prevents HSP90/NPM-ALK interaction,
it results in the rapid association of HSP70 with NPM-ALK and
NPM-ALK targeting for proteasomal degradation (Bonvini, 2004).
Angiogeneic mediators
The transcription factor, hypoxia-inducible factor-1 (HIF-1), exists
as a heterodimer composed of a constitutively expressed b-subunit
and an oxygen-sensing a-subunit (Ebert and Bunn, 1998).
Hypoxia-inducible factor-1a accumulates during hypoxia and
dimerises with HIF-1b before translocating to the nucleus and
binding hypoxia response elements on hypoxia-responsive genes
(Ebert and Bunn, 1998). Genes regulated by HIF1-a are key players
in cancer development and include many angiogenic mediators
(nitric oxide synthase and vascular endothelial growth factor
(VEGF)), genes involved in cellular matrix metabolism (urokinase-
type plasminogen activator receptor, matrix metalloproteinases-2
MMP2) and glycolysis (phosphoglycerate kinase-1 and lactate
dehydrogenase; Weidemann and Johnson, 2008). The hypoxic
microenvironment of tumours means that HIF-1a is often over-
expressed. In normoxia, HIF-1a is ubiquitinated and degraded.
Similarly, HSP90 inhibitors promote HIF-1a degradation and are
more cytotoxic in hypoxic conditions (Cao et al, 2008).
Apoptotic mediators
Apoptosis is a highly regulated cell death programme triggered by
a diverse array of cellular stresses. Apoptotic signal transduction
pathways converge to activate a conserved family of aspartic acid-
specific cysteine proteases called caspases (Samali et al, 1999).
Cells undergo apoptosis through one of the two major signalling
pathways. The first, the intrinsic or mitochondrial pathway, is
regulated by the Bcl-2 family proteins. Mitochondrial disturbance
culminates in the release of cytochrome c, procaspases and other
proapoptotic factors, and results in the formation of a caspase-
activating complex called apoptosome. The extrinsic or death
receptor-mediated pathway, is initiated by binding of an extra-
cellular ligand (tumour necrosis factor-a (TNF-a) or TNF-
related apoptosis-inducing ligand; TRAIL), formation of the
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(Samali et al, 1999).
Heat-shock proteins negatively regulate apoptosis. Heat-shock
protein 90 promotes cell survival by activation of NF-kB. Tumour
necrosis factor-a activation recruits and stabilises receptor-
interacting protein (RIP) at the TNF receptor-1 to maintain NF-
kB activity (Lewis et al, 2000). Key signalling molecules, such as
VEGF, induces antiapoptotic protein Bcl-2 expression and
stimulates HSP90 association with Bcl-2 and Apaf-1 to inhibit
apoptosis (Dias et al, 2002). Therefore, HSP inhibitors may
enhance apoptosis and circumvent resistance to anticancer
treatments, such as TNFa and TRAIL.
Tumour suppressor genes
As a transcription factor, p53 is activated in response to DNA-
damage-inducing stresses. Once active, p53 will induce cell cycle
arrest or apoptosis through its regulation of p53-responsive genes
(p21, p27, Bax, Puma, Noxa; Vogelstein et al, 2000). Over 50% of
human cancers possess mutated p53 and in particular are
associated with the more aggressive or chemotherapeutic resis-
tant tumours (Vogelstein et al, 2000). Heat-shock protein 90 and
HSP70 co-precipitate with mutant p53 (Whitesell et al, 1998).
Heat-shock protein binding to mutant p53 inhibits mouse
double minute 2-induced ubiquitination and degradation of p53.
Heat-shock protein 90 inhibitors disrupt these interactions
and result in p53 degradation (Whitesell et al, 1998). Therefore,
HSP90 inhibitors could ensure that DNA-damage-inducing
agents are more effective in the eradication of tumours with
mutated p53.
Cell cycle regulatory proteins
Cellular division is carefully monitored by cell cycle checkpoints,
which are regulated by cyclins, cyclin-dependent kinases (CDK)
and CDK inhibitors (Malumbres and Barbacid, 2001). In addition,
retinoblastoma (Rb) and the E2F transcription factor regulate the
G1/S transition. Retinoblastoma phosphorylation is crucial to cell
cycle progression. When unphosphorylated, Rb blocks cell
proliferation by altering E2F function. When phosphorylated, Rb
is inactive and so the cell cycle proceeds (Malumbres and
Barbacid, 2001). CDK4 phosphorylates Rb and is a client protein
of HSP90. Heat-shock protein 90 inhibition targets CDK4 for
proteasomal degradation allowing Rb to remain unphosphorylated
(Srethapakdi et al, 2000).
Telomeres are non-coding DNA regions found at the ends of
chromosomes, which contain several thousand short tandem
repeats. Following a replication cycle, the telomere on each
chromosome will lose 50–100bp. This progressive shortening of
telomere length eventually effects chromosome stability and leads
to cell death (Xu and Neckers, 2007). In transformed cells,
telomere shortening is prevented by the increased presence of
telomerase, which consists of a catalytic protein component,
human telomerase reverse transcriptase (hTERT) and a template-
containing RNA (Xu and Neckers, 2007). Heat-shock protein 90
inhibition perturbs telomerase assembly and hTERT enzymatic
activity to reduce the proliferative capacity of tumours (Xu and
Neckers, 2007).
Mediators of tissue invasion and metastasis
Tumour invasion and metastasis require the upregulation of
MMP2 and Met proto-oncogenes. The protein product of Met is
the transmembrane tyrosine kinase p190
Met, a receptor for
hepatocyte growth factor/scatter factor (HGF/SF) and client
protein of HSP90. Binding of HGF/SF to p190
Met increases cellular
proliferation, migration, invasion and morphogenesis (Bottaro
et al, 1991). Metastasis requires tumour cell adhesion to the
extracellular matrix, digestion of the matrix and migration of the
tumour cells. These processes are regulated by HSP90 client
protein, MMP2 (Xu and Neckers, 2007). Heat-shock protein 90
inhibitors downregulate p190
Met expression, inhibit HGF/SF-
mediated cell motility and impair MMP2 maturation
(Webb et al, 2000).
CONCLUSION
It is clear that HSP90 play a crucial role in maintaining oncogenic
protein homoeostasis. Heat-shock protein 90 inhibition offers
great promise in the treatment of a wide variety of solid and
haematological malignancies. Various HSP90 inhibitors have
entered clinical trials and have been recently reviewed (Powers
and Workman, 2007; Solit and Chiosis, 2008), but many crucial
questions remain: Will newer synthetic HSP90 inhibitors be more
potent in cancer cells than non-transformed cells? What current
pharmacodynamic indicators could be used to ascertain the
optimal dosing regime? Is the induction of HSP70 in PBL a
sufficiently good marker of biological activity following HSP90
inhibition? And would the induction of HSP70 amongst other
HSPs decrease HSP90 inhibitor efficacy?
Emphasis has also been placed on the therapeutic targeting of
other key molecules in the multichaperone protein complexes. As
HSF1 regulates the expression of a number of HSPs, there has been
increased interest in the development of small molecule mod-
ulators that could alter HSF1 activity and as a consequence HSP
expression (Powers and Workman, 2007). Natural-acting flavo-
noid, quercetin; the benzylidene lactam, KNK437; the diterpene
triepoxide triptolide and the dehydroemetine derivative NZ28 and
emunin have been used to target HSF1 activity, although the
specificity and potency of these compounds are still questionable
(Powers and Workman, 2007). Furthermore, decreasing the
normal expression levels of HSPs by HSF1 inhibition raises
concerns about toxicity to non-transformed cells.
In view of HSP70 induction observed with HSP90 inhibitor
treatment, the potential therapeutic benefit of modulating HSP70
activity has become attractive. As yet, there are limited small
molecules inhibitors of HSP70 available; however, it would be
interesting to combine HSP90 and HSP70 inhibitors that would
target HSP90 and both HSC70 and HSP72 isoforms to enhance
tumour response to these agents.
Early clinical trials have highlighted toxicities ranging from
constitutional symptoms such as fatigue to hepatic and
gastrointestinal adverse events, which have all been well
tolerated (Solit and Chiosis, 2008). However, the long-term
effects of HSP90 inhibition needs to be evaluated further as
clinical trials mature in view of the importance of HSP90 in
cellular functions and maintaining genomic stability of non-
transformed cells.
In designing future clinical trials, clinical investigators will
need to incorporate appropriate radiological and pathological
parameters to determine the response to HSP inhibitors. This
would include the use of FDG-PET and DCE-MRI to document
tumour activity and avoid misinterpreted tumour responses
from a CT alone. Pathological information on mutational status
of RTK and p53 mutations or expression levels of key sig-
nalling molecules, such as EGFR, HER-2 and HIF-1 expression,
should also be obtained to select appropriate patient popu-
lations. These key signalling molecules may serve as predictive
markers for HSP90 inhibitor therapy and its expression levels
before and after therapy for both responders and non-
responders should be documented using effective and repro-
ducible molecular biology assays. This will help determine
optimal biological dosing, preventing toxicity to normal cells
and will improve efficacy of HSP90 inhibitors in various
tumour types.
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developed based on preclinical data. Combinations of HSP90 inhib-
itors with conventional chemotherapy or targeted therapies, such as
proteasomal inhibitors, HDACi, small molecule RTK inhibitors or
TRAIL, may lead to greater efficacy and improved clinical outcomes.
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